Aelis Farma Announces the Inclusion of the 1st Patient in a Phase 2b Study of AEF0117 for the Treatment of Cannabis Use Disorder (CUD)
BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Mnemonic: AELIS) (Paris:AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatment for brain diseases, announces the enrollment of the…